2016
Prevention of Variceal Rebleeding: Stratifying Risk and Individualizing Care
Albillos A, Abraldes J, Ripoll C, Reiberger T, Augustin S, Salerno F, Moreau R, Garcia-Tsao G. Prevention of Variceal Rebleeding: Stratifying Risk and Individualizing Care. 2016, 311-316. DOI: 10.1007/978-3-319-23018-4_31.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsStandard of careCombination therapyVariceal rebleedingVariceal ligationChild AChild B/C patientsChild B/CSecond-line therapyStandard combination therapyIndividual patient dataLow rebleedingVariceal bleedC patientsPortal hypertensionCirrhotic patientsLine therapyRisk stratificationTailor therapySuch therapyTherapyRebleedingPatientsPatient dataCarePrevention
2008
Prediction of clinical outcomes in primary biliary cirrhosis by serum enhanced liver fibrosis assay
Mayo MJ, Parkes J, Adams‐Huet B, Combes B, Mills AS, Markin RS, Rubin R, Wheeler D, Contos M, West AB, Saldana S, Getachew Y, Butsch R, Luketic V, Peters M, Di Bisceglie A, Bass N, Lake J, Boyer T, Martinez E, Boyer J, Garcia‐Tsao G, Barnes D, Rosenberg WM. Prediction of clinical outcomes in primary biliary cirrhosis by serum enhanced liver fibrosis assay. Hepatology 2008, 48: 1549-1557. PMID: 18846542, PMCID: PMC2597274, DOI: 10.1002/hep.22517.Peer-Reviewed Original ResearchConceptsPrimary biliary cirrhosisSerum fibrosis markersBiliary cirrhosisLiver biopsyClinical progressionFibrosis markersLiver fibrosisPrognostic informationPrognostic performanceSerial liver biopsy specimensEnd-stage liver diseaseLong-term prognostic informationLiver-related deathPositive antimitochondrial antibodyMayo risk scoreEvent-free survivalAppropriate clinical settingSerum hyaluronic acidEnhanced liver fibrosisLiver biopsy specimensAccurate noninvasive measureFibrosis algorithmsPBC subjectsVariceal bleedBiopsy complications